STRATA Skin Sciences Q1 revenue up 8.6% to $7.6M; net loss widens to $2.8M

STRATA Skin Sciences, Inc.

2023-Q1 EPS reported -$0.08 revenue$7,567,000

Revenue of $7.6M vs $7.0M YoY; global recurring revenue $5.2M, equipment revenue $2.4M.
Net loss of $2.8M ($0.08 loss per share) vs net loss of $2.5M ($0.07 per share) YoY.
Launched TheraClear X in Jan 2023; placed 44 devices in Q1, total 58 U.S. placements.
Sold over 3,000 TheraClear treatments in Q1; signed India distribution deal with Spectra Medical.
Full-year 2023 revenue guidance reaffirmed at $38M–$40M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

STRATA Skin Sciences, Inc. reported first quarter ended March 31, 2023 results: revenue $7.6 million, net income $2.8 million, EPS loss of $0.08 per basic and diluted common share. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $7.6 million
Net income: $2.8 million
EPS: loss of $0.08 per basic and diluted common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

EXHIBIT 99.1 Exhibit 99.1 Press Release dated May 15, 2023 issued by STRATA Skin Sciences, Inc. STRATA Skin Sciences Reports First Quarter 2023 Revenue Achieved revenue of $7.6 million for the first quarter 2023 Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences,

View on SEC.gov

Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-024714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.